These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

368 related articles for article (PubMed ID: 26739049)

  • 1. The High Degree of Sequence Plasticity of the Arenavirus Noncoding Intergenic Region (IGR) Enables the Use of a Nonviral Universal Synthetic IGR To Attenuate Arenaviruses.
    Iwasaki M; Cubitt B; Sullivan BM; de la Torre JC
    J Virol; 2016 Jan; 90(6):3187-97. PubMed ID: 26739049
    [TBL] [Abstract][Full Text] [Related]  

  • 2. General Molecular Strategy for Development of Arenavirus Live-Attenuated Vaccines.
    Iwasaki M; Ngo N; Cubitt B; Teijaro JR; de la Torre JC
    J Virol; 2015 Dec; 89(23):12166-77. PubMed ID: 26401045
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Arenavirus Genome Rearrangement for the Development of Live Attenuated Vaccines.
    Cheng BY; Ortiz-Riaño E; de la Torre JC; Martínez-Sobrido L
    J Virol; 2015 Jul; 89(14):7373-84. PubMed ID: 25972555
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of live-attenuated arenavirus vaccines based on codon deoptimization.
    Cheng BY; Ortiz-Riaño E; Nogales A; de la Torre JC; Martínez-Sobrido L
    J Virol; 2015 Apr; 89(7):3523-33. PubMed ID: 25589652
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Lassa Virus Live-Attenuated Vaccine Candidate Based on Rearrangement of the Intergenic Region.
    Cai Y; Iwasaki M; Motooka D; Liu DX; Yu S; Cooper K; Hart R; Adams R; Burdette T; Postnikova EN; Kurtz J; St Claire M; Ye C; Kuhn JH; Martínez-Sobrido L; de la Torre JC
    mBio; 2020 Mar; 11(2):. PubMed ID: 32209677
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular Engineering of a Mammarenavirus with Unbreachable Attenuation.
    Sakabe S; Cubitt B; Martinez-Sobrido L; de la Torre JC
    J Virol; 2023 Jan; 97(1):e0138522. PubMed ID: 36533953
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of live-attenuated arenavirus vaccines based on codon deoptimization of the viral glycoprotein.
    Cheng BYH; Nogales A; de la Torre JC; Martínez-Sobrido L
    Virology; 2017 Jan; 501():35-46. PubMed ID: 27855284
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular and cell biology of the prototypic arenavirus LCMV: implications for understanding and combating hemorrhagic fever arenaviruses.
    de la Torre JC
    Ann N Y Acad Sci; 2009 Sep; 1171 Suppl 1():E57-64. PubMed ID: 19751403
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel strategies for development of hemorrhagic fever arenavirus live-attenuated vaccines.
    Martinez-Sobrido L; de la Torre JC
    Expert Rev Vaccines; 2016 Sep; 15(9):1113-21. PubMed ID: 27118328
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Envelope exchange for the generation of live-attenuated arenavirus vaccines.
    Bergthaler A; Gerber NU; Merkler D; Horvath E; de la Torre JC; Pinschewer DD
    PLoS Pathog; 2006 Jun; 2(6):e51. PubMed ID: 16751848
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification and Mechanism of Action of a Novel Small-Molecule Inhibitor of Arenavirus Multiplication.
    Ngo N; Henthorn KS; Cisneros MI; Cubitt B; Iwasaki M; de la Torre JC; Lama J
    J Virol; 2015 Nov; 89(21):10924-33. PubMed ID: 26292327
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A multivalent vaccination strategy for the prevention of Old World arenavirus infection in humans.
    Botten J; Whitton JL; Barrowman P; Sidney J; Whitmire JK; Alexander J; Kotturi MF; Sette A; Buchmeier MJ
    J Virol; 2010 Oct; 84(19):9947-56. PubMed ID: 20668086
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Lassa Fever Live-Attenuated Vaccine Based on Codon Deoptimization of the Viral Glycoprotein Gene.
    Cai Y; Ye C; Cheng B; Nogales A; Iwasaki M; Yu S; Cooper K; Liu DX; Hart R; Adams R; Brady T; Postnikova EN; Kurtz J; St Claire M; Kuhn JH; de la Torre JC; Martínez-Sobrido L
    mBio; 2020 Feb; 11(1):. PubMed ID: 32098811
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluating the immunogenicity and protective efficacy of a DNA vaccine encoding Lassa virus nucleoprotein.
    Rodriguez-Carreno MP; Nelson MS; Botten J; Smith-Nixon K; Buchmeier MJ; Whitton JL
    Virology; 2005 Apr; 335(1):87-98. PubMed ID: 15823608
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of Reverse Genetics for the Prototype New World Mammarenavirus Tacaribe Virus.
    Ye C; de la Torre JC; Martínez-Sobrido L
    J Virol; 2020 Sep; 94(19):. PubMed ID: 32669332
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An mRNA-LNP-based Lassa virus vaccine induces protective immunity in mice.
    Hashizume M; Takashima A; Iwasaki M
    J Virol; 2024 Jun; 98(6):e0057824. PubMed ID: 38767352
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Residues K465 and G467 within the Cytoplasmic Domain of GP2 Play a Critical Role in the Persistence of Lymphocytic Choriomeningitis Virus in Mice.
    Iwasaki M; Ng CT; Cubitt B; de la Torre JC
    J Virol; 2016 Nov; 90(22):10102-10112. PubMed ID: 27581982
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reverse Genetics Approaches to Control Arenavirus.
    Martínez-Sobrido L; Cheng BY; de la Torre JC
    Methods Mol Biol; 2016; 1403():313-51. PubMed ID: 27076139
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Arenavirus Quasispecies and Their Biological Implications.
    Grande-Pérez A; Martin V; Moreno H; de la Torre JC
    Curr Top Microbiol Immunol; 2016; 392():231-76. PubMed ID: 26472215
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An attenuated Machupo virus with a disrupted L-segment intergenic region protects guinea pigs against lethal Guanarito virus infection.
    Golden JW; Beitzel B; Ladner JT; Mucker EM; Kwilas SA; Palacios G; Hooper JW
    Sci Rep; 2017 Jul; 7(1):4679. PubMed ID: 28680057
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.